Orismilast, an oral PDE4 inhibitor, has been explored not only for psoriasis (Table 1) but also for atopic dermatitis and hidradenitis suppurativa during phase 1 and 2 clinical trials [25]. This evidence concerns the gene PDE4A and atopic eczema.